Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Erythromelalgia
Interventions
Amitriptyline Hydrochloride, Placebo
Drug
Lead sponsor
AlgoTherapeutix
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Schizophrenia
Interventions
1 Hz rTMS Stimulation, Sham rTMS Stimulation
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana
Conditions
Episodic Migraine, Chronic Migraine
Interventions
Corabotase, Placebo, Corabotase dose A, Corabotase dose B
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
71
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 54 more
Conditions
Exercise-induced Muscle Soreness, Exercise-induced Joint Pain, Exercise-induced Joint Stiffness, Exercise-induced Cartilage Turnover
Interventions
NEM® brand eggshell membrane powder, curQ+® brand highly absorbable curcumin, EM Placebo, Curc Placebo, NEM® plus curQ+® combination
Dietary Supplement
Lead sponsor
ESM Technologies, LLC
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
College Station, Texas
Conditions
Migraine Prophylaxis
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Huntsville, Alabama • Long Beach, California • San Diego, California + 26 more
Conditions
Primary Erythromelalgia, Inherited Erythromelalgia
Interventions
XPF-002, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
19 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Anniston, Alabama
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,890 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 75 more
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
38
States / cities
San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 32 more
Completed Phase 2 Interventional Results available

ERG/5-HTP in Fragile X Syndrome (FXS)

NCT05030129
Conditions
Fragile X Syndrome
Interventions
5-Hydroxytryptophan, Ergoloid Mesylates, Matching placebo for Ergoloid mesylates, Matching placebo for 5-Hydroxytryptophan
Drug
Lead sponsor
Elizabeth Berry-Kravis
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois